The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...
Stocktwits on MSN14d
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The DipShares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after missing Wall Street estimates on both revenue and profit in its latest ...
Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...
On the call, Recursion highlighted REC-7735 preclinical data, suggesting differentiation from Scorpion Therapeutics’ STX-478, which was acquired by Eli Lilly (LLY) earlier this year. To moderate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback